Multiply Labs Closes $75 Million Round to Automate Drug Manufacturing

The raise signals growing investor appetite for robotics solutions in pharmaceutical production, a segment where manual processes remain the norm for complex therapies such as gene therapies and...

San Francisco-based robotics startup Multiply Labs closed a $75 million funding round to scale automated manufacturing of complex pharmaceuticals, including gene therapies and mRNA treatments, according to a Business Insider report published October 2026 that reviewed the company's investor pitch deck.

The round was backed by investors including Founders Fund and AstraZeneca, according to the same Business Insider report. The participation of AstraZeneca, a large pharmaceutical company with US commercial operations, indicates strategic as well as financial interest in the technology. The specific valuation assigned to Multiply Labs in connection with this round was not disclosed in the available source material.

Multiply Labs was founded by CEO Fred Parietti and is headquartered in San Francisco, California. The company builds robotic systems designed to handle the production of drugs that are difficult or impossible to manufacture at scale through conventional methods. Gene therapies and mRNA treatments are among the drug classes the company's systems are designed to produce, per the Business Insider report.

The pharmaceutical manufacturing market in the United States has faced persistent capacity and quality control pressures. The US Food and Drug Administration has documented ongoing drug shortages tied in part to manufacturing failures; the FDA's drug shortage database, maintained at fda.gov, listed more than 100 active shortages as of mid-2026. Automation in drug production is broadly viewed within the industry as one mechanism for reducing batch failure rates, though independent data on Multiply Labs' specific yield performance was not available in the source material reviewed.

Complex biologics such as gene therapies and mRNA vaccines require precise environmental controls and multi-step processes that have historically relied on skilled human labor. That labor intensity contributes to high per-unit production costs. The pitch deck reviewed by Business Insider shows the company positioned its robotic platform as a solution to that cost and consistency problem, though the deck's specific financial projections were not reproduced in the available source excerpt.

Founders Fund, one of the disclosed investors, is a venture capital firm based in San Francisco with prior investments in technology and life sciences companies. AstraZeneca operates a significant US commercial and research presence, including manufacturing sites in the United States. The combination of a financial venture investor and a strategic pharmaceutical backer in the same round is a common structure for life sciences hardware companies seeking both capital and industry partnership, though it does not guarantee a future commercial relationship between Multiply Labs and AstraZeneca beyond the investment itself.

The $75 million figure represents a Series-level private financing. Because Multiply Labs is a private company, it is not required to file financial statements with the US Securities and Exchange Commission, and no SEC filings were available to verify revenue, burn rate, or profitability. What would reveal those figures is either a future SEC registration statement or a voluntary disclosure by the company.

The broader US market for pharmaceutical manufacturing automation has drawn increased investment in recent years. According to a 2025 report from the Pharmaceutical Research and Manufacturers of America (PhRMA), US biopharmaceutical companies invested approximately $106 billion in research and manufacturing in 2024. The share directed toward manufacturing automation specifically was not broken out in that report.

Investors and pharmaceutical companies tracking this segment will watch whether Multiply Labs converts its raised capital into signed manufacturing contracts with drugmakers, which would provide the first public evidence of commercial traction. No customer contracts were disclosed in the source material available for this story.

The US market context matters for investors because any drugs manufactured by Multiply Labs' systems for sale in the United States would require FDA approval of the manufacturing process itself, not only the drug. The FDA's Current Good Manufacturing Practice regulations govern how pharmaceutical production equipment and processes must be validated, adding a regulatory timeline to any commercial scale-up.